Document is current
Any future updates will be listed below
-
Authors
Oñate, Guadalupe https://orcid.org/0000-0003-2180-2371
Garrido, Ana
Arnan, Montserrat
Pomares, Helena
Alonso, Ester
Tormo, Mar https://orcid.org/0000-0001-9622-1649
Diaz-Beya, Marina
Vives, Susana
Zamora, Lurdes
Sampol, Antonia https://orcid.org/0000-0001-7465-6203
Coll, Rosa
Salamero, Olga https://orcid.org/0000-0003-3237-0025
Cervera, Marta
Garcia, Antoni
Vall-Llovera, Ferran
Garcia-Avila, Sara
Bargay, Joan
Ortin, Xavier
Iranzo, Eva
Guijarro, Francisca https://orcid.org/0000-0001-6376-0929
Pratcorona, Marta
Nomdedeu, Josep F. https://orcid.org/0000-0003-3399-346X
Esteve, Jordi
Sierra, Jorge https://orcid.org/0000-0002-7966-0356
-
Funding
Funding for this research was provided by:
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (PERIS SLT00433, SGR 01139 2021)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/01246, PI20/01621)
- License Information
-
More Information
Article History
Received: 17 October 2024
Revised: 27 November 2024
Accepted: 6 December 2024
First Online: 11 January 2025
Competing interests
: JS is member of the speaker bureau and advisory board of Jazz Pharmaceuticals, Astellas, Abbvie and Pfizer. JE reports participation in Advisory Boards of Abbvie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, Amgen and research grants from Novartis, Jazz Pharmaceuticals and Pfizer. The remaining authors declare no competing financial interests.
